Ioxilan

Ioxilan is a diagnostic radiopaque media used for cerebral arteriography, coronary arteriography and left ventriculography, visceral angiography, aortography, peripheral arteriography, excretory urography, and contrast enhanced computed tomographic (CECT) imaging of the head and body.

• Ioxilan is available under the following different brand names: Oxilan

Common side effects of Ioxilan include:

• headache
• fever
• swelling, hematoma or bloot clot at the injection site
• chills
• chest pain or discomfort
• high blood pressure (hypertension)
• low blood pressure (hypotension)
• slow or irregular heart rate
• nausea
• vomiting
• diarrhea
• dizziness
• rash
• hives
• itching
• Serious side effects of Ioxilan include:
• hives
• difficulty breathing
• swelling of the face, lips, tongue, or throat
• high or low blood pressure
• slow or irregular heart rate
• nausea
• vomiting
• diarrhea
• dizziness
• rash
• itching

Rare side effects of Ioxilan include:

• none 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Injectable solution

• 300 mgI/mL (62%)
• 350 mgI/mL (73%)

CECT Imaging

Adult dosage

• CECT of the Head
  • 30-60 g iodine indicated
  • Oxilan 300: 100-200 mL IV
  • Oxilan 350: 86-172 mL IV
  • Not to exceed 200 mL
• CECT of the Body
  • 15-60 g iodine indicated
  • Oxilan 300: 50-200 mL IV
  • Oxilan 350: 43-172 mL IV
  • Not to exceed 200 mL
• Cerebral Arteriography
  • 8-12 mL intra-arterially (2.4-3.6 g iodine); not to exceed 150 mL
• Intra-arterial administration
  • Oxilan 350 is indicated
  • Left and right coronary arteries: 2-10 mL (0.7-3.5 g iodine)
  • Left ventricle: 25-50 mL (8.75-17.5 g iodine)

Dosage Considerations – Should be Given as Follows:

• See "Dosages"

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, healthcare provider, or pharmacist first.

• Ioxilan has no noted severe interactions with any other drugs
• Ioxilan has no noted serious interactions with any other drugs
• Ioxilan has no noted moderate interactions with any other drugs
• Ioxilan has no noted minor interactions with any other drugs

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, or if you have health questions or concerns.

Contraindications

• Hypersensitivity to product or components
• Intrathecal administration (potentially fatal)

Effects of drug abuse

• None

Short-Term Effects

• See "What Are Side Effects Associated with Using Ioxilan?"

Long-Term Effects

• See "What Are Side Effects Associated with Using Ioxilan?"

Cautions

• Caution in severe renal impairment, combined renal/hepatic disease, thyroid dysfunction, multiple myeloma, anuria, pheochromocytoma, sickle cell, congestive heart failure, severe arterial/venous disease
• Severe cutaneous adverse reactions (SCAR), including Stevens-Johnson syndrome and toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms may develop from 1 hour to several weeks after intravascular contrast agent administration; reaction severity may increase and time to onset may decrease with repeat administration of contrast agent; prophylactic medications may not prevent or mitigate SCAR; avoid administering product to patients with history of severe cutaneous adverse reaction to product
• May cause renal failure in patients with advanced vascular disease and diabetes; should be well hydrated before/after the procedure
• Hypersensitivity to contrast medium, iodine
• Myocardial infarctions and stroke reported with angiographic procedures
• Avoid extravasation, especially in patients with severe arterial or venous disease
• Inhibits blood coagulation (less than ionic contrast media in vitro)
• Allergies (bronchial asthma, hay fever, food allergies)

Pregnancy and Lactation

• May be acceptable during pregnancy
• Lactation
  • Not known; use caution